RIGL

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company founded in 1996 and incorporated in South San Francisco, California. The company went public in November 2000 and has evolved from a drug discovery company into a commercial-stage biopharmaceutical company focused on developing and commercializing small molecule drugs for hematologic disorders, cancer, and rare immune diseases. After years of research and development, Rigel achieved its first commercial success with the approval of <b>Tavalisse</b> for immune thrombocytopenia and has since expanded its commercial portfolio to include three marketed products while maintaining an active pipeline of investigational drugs.